文献速递急性肾损伤肾小球疾病

血浆置换与糖皮质激素对ANCA相关血管炎患者早期肾功能的影响:PEXIVAS试验事后分析

The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial.
PubMed 文献 · Kidney Int · 2024-12-19

该事后分析基于PEXIVAS随机对照试验,纳入691例ANCA相关肾小球肾炎患者,其中349例接受血浆置换(PLEX),342例未接受。结果显示,PLEX组在治疗开始后第2、4、8周的平均eGFR改善均大于非PLEX组,第4周肾功能恢复(eGFR增加≥15ml/min/1.73m2)的差异最显著(RR 1.41,95%CI 1.09-1.82)。第4周eGFR增加或肾功能恢复与第52周终末期肾病风险降低显著相关。

要点

  • PLEX可改善ANCA相关肾小球肾炎患者的早期肾功能。
  • 第4周肾功能恢复在PLEX组更显著(RR 1.41,95%CI 1.09-1.82)。
  • 第4周肾功能改善与第52周终末期肾病风险降低相关。

核心结论

  • PLEX可改善ANCA相关肾小球肾炎患者的早期肾功能,且第4周肾功能恢复与第52周终末期肾病风险降低显著相关。

研究设计与样本

  • PEXIVAS试验的事后分析,纳入691例ANCA相关肾小球肾炎患者,349例接受PLEX,342例未接受PLEX。

主要发现

  • PLEX组在治疗开始后第2、4、8周的平均eGFR改善均大于非PLEX组。
  • 第4周肾功能恢复在PLEX组 vs 非PLEX组的相对风险(RR)为1.41(95%CI 1.09-1.82)。
  • 第4周eGFR增加或肾功能恢复与第52周终末期肾病风险降低显著相关(RR分别为0.96,95%CI 0.95-0.97;0.29,95%CI 0.16-0.52)。
  • 减量糖皮质激素组与标准剂量组之间,eGFR变化或肾功能恢复无差异。

关键数值与推荐

  • 肾功能恢复定义为eGFR增加≥15ml/min/1.73m2。
  • 基线eGFR在PLEX组为21.7±20.3ml/min/1.73m2,非PLEX组为20.6±18.7ml/min/1.73m2。

临床怎么用

  • 对于ANCA相关肾小球肾炎伴肾脏受累患者,可考虑PLEX以改善早期肾功能。
  • 早期肾功能恢复(第4周)可能提示远期终末期肾病风险降低。

局限性

  • 本研究为事后分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic plasma exchange (PLEX) is an adjunctive treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and kidney involvement. Little is known about the effect of PLEX on early changes in kidney function. This post-hoc analysis of the PEXIVAS trial investigated the effects of PLEX on changes in kidney function within 12 months. PEXIVAS was a randomized controlled trial recruiting 691 patients with ANCA-associated glomerulonephritis, of whom 349 underwent PLEX and 342 received no-PLEX. The primary outcomes of this post hoc study of PEXIVAS were change in estimated glomerular filtration rate (eGFR) from baseline and recovery of kidney function (defined as eGFR increase of 15ml/min/1.73m2 or more). Baseline eGFR was 21.7 ± 20.3 and 20.6 ± 18.7 ml/min/1.73m2 in the PLEX and no-PLEX groups, respectively. Mean improvements in eGFR at weeks two, four, and eight after initiation of therapy were greater for the PLEX vs. the no-PLEX groups. The greatest significant difference in recovery of kidney function in the PLEX compared to the no-PLEX groups was at week four (relative risk (RR): 1.41; 95% confidence interval:1.09-1.82). Increased eGFR or recovery of kidney function at week four were significantly associated with lower risk for end-stage kidney disease at week 52 (RR: 0.96: 0.95-0.97, and RR: 0.29: 0.16-0.52; respectively). Neither changes in eGFR nor recovery of kidney function differed by reduced- compared to standard-dose glucocorticoid group. Overall, our study indicates that PLEX improves early kidney function in patients with ANCA-associated glomerulonephritis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Odler B, Riedl R, Geetha D, et al. The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial. Kidney Int. 2024. PMID: 39708998. doi:10.1016/j.kint.2024.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。